Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Northwestern University
Sponsor:
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
NCT01478321
First received: November 17, 2011
Last updated: May 5, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2017
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)